solfia.org
Serum Level of Interleukin-17 in Autoimmune Hepatitis in Children (GJGHv3n1a3) - synergy - synergy

Serum Level of Interleukin-17 in Autoimmune Hepatitis in Children Pages 7-13

Yasser K. Rashed1, Mohamed A. El Guindi1, Magdy A. Saber1, Ann S. Farid2 and Bassam A. Ayuob1

1Pediatric Hepatology Department; 2Clinical Pathology Department, National Liver Institute, Menoufiya University, Egypt

http://dx.doi.org/10.12970/2308-6483.2015.03.01.3

Abstract: Background/Aims: Autoimmune hepatitis (AIH) is a chronic, generally progressive inflammatory disease of the liver that affects both adults and children. Th17 cells can produce multiple cytokines including IL-17A (also known as IL-17), IL-17F, IL-21 and IL-22. IL-17, a major effector cytokine of Th17 cells, is involved in mobilizing, recruiting, and activating neutrophils and leads to massive tissue inflammation. IL-17, a major effector cytokine of Th17 cells, is involved in mobilizing, recruiting, and activating neutrophils and leads to massive tissue inflammation. The aim is to estimate the serum level of Interleukin-17 (IL17) in children with autoimmune hepatitis (AIH) to investigate its possible role in the pathogenesis of AIH.

Patients and Method: Ninety children, sixty of them were recruited from the outpatient and inpatient clinics of Pediatric Hepatology department – National Liver Institute from October 2011 till October 2012 and thirty of them were volunteers from a school. Investigated for the diagnosis of chronic liver diseases and serum level IL17.

Results: IL-17 serum level was significantly higher in AIH group than CLD and control groups. It was significantly higher in non-responders AIH than responders. IL-17 level at cutoff value of 99.95 pg/ml can discriminate between AIH and non-AIH groups with 96.7% sensitivity, 95% specificity, 90.9% positive predictive value (PPV), 100% negative predictive value (NPV) and 96.6% accuracy.

Conclusion: IL-17 serum level was significantly higher in children with autoimmune hepatitis (AIH). New lines of treatment can emerge targeting Th17 cells and IL-17 in order to reduce the ongoing autoimmune inflammatory process in the liver and to prevent progression of fibrosis.

Keywords: Autoimmune hepatitis, interleukin 17, chronic liver diseases (CLD). Read more →

  • Why Choose Synergy

    Synergy Publishers opens a portal to researchers and scholarly communities We aspire to be one of the best publishers for professional and scholarly societies. We maintain a balanced, independent editorial policy being fully committed to authors with honesty. We strive to proceed in a manner that is conducive to a sustainable future.